Phase 4 N=2,997 XIENCE V® USA Dual Antiplatelet Therapy (DAPT) Cohort
Chronic Total Occlusion of Coronary Artery · Vascular Disease · Myocardial Ischemia
Primary: Incidence of Composite of All Death, MI and Stroke (Defined as MACE)
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=15 Akt Inhibitor MK2206, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Chronic Lymphocytic Leukemia · Recurrent Small Lymphocytic Lymphoma · Refractory Chronic Lymphocytic Leukemia
Primary: Number of Phase I Participants With Dose-Limiting Toxicity Events (Phase I) — 1; 2 Patients reporting Dose-Limiting Events
Phase 2 N=338 Evaluation of Umeclidinium Bromide in Combination With Fluticasone Furoate in COPD Subjects With an Asthmatic Component
Pulmonary Disease, Chronic Obstructive
Primary: Change From Baseline in Clinic Trough Forced Expiratory Volume in One Second (FEV1) at the End of Treatment Phase A (Visit 6/Day 29) — 0.047; 0.146; 0.193; 0.175 Liters…
N/A N=359 Observational Program to Assess Respiratory Syncytial Virus (RSV) Hospitalization Rate in Population of Children at High-risk of Serious RSV Illness Who Received Palivizumab Immunoprophylaxis
Respiratory Syncytial Virus (RSV)
Primary: Proportion of Infants Hospitalized for Lower Respiratory Tract Infection (LRTI) With a Positive Respiratory Syncytial Virus (RSV) Diagnostic Test — 1 participants
N/A N=20 Differential Effects of Clomiphene Citrate in Women Undergoing Superovulation
Mood
Primary: Follicular Cycle Total Behavioral Score for Calendar of Premenstrual Experiences (COPE) Self Assessment — 3; 5 units on a scale
Phase 2 N=9 rTMS and Retraining in Focal Hand Dystonia
Focal Dystonia
Primary: Change From Baseline in Global Rating of Change at Posttest (Day 5) — 1.3; 1.2 units on a scale
Phase 3 N=85 Trial of Late Surfactant to Prevent BPD: A Pilot Study in Ventilated Preterm Neonates Receiving Inhaled Nitric Oxide
Respiratory Distress Syndrome of Prematurity (Surfactant Dysfunction) · Bronchopulmonary Dysplasia
Primary: SP-B Content — 19.9; 13.3 Total surfactant protein (% of PL)
N/A N=115 A Clinical Trial Using Spy Elite System in Planning Tissue Advancement Flaps After Ventral Hernia Repair
Ventral Hernia
Primary: Number of Participants With Wound Complications — 16; 17 participants
Phase 1 N=34 A Single Rising Dose Study of MK-8150 (MK-8150-001)
Hypertension · Isolated Systolic Hypertension (ISH)
Primary: Number of Participants With an Adverse Event (AE) — 8; 8; 7; 7 participants
Phase 2 N=8 Glutamatergic Modulation of Cocaine-related Deficits
Cocaine Dependence
Primary: Change in Cue Reactivity — 126; 18; 16 units on a scale (0-200), high is worse
Phase 3 N=511 Study to Evaluate the Efficacy and Safety of Reslizumab Treatment in Patients With Moderate to Severe Asthma
Eosinophilic Asthma
Primary: Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) at Week 16 in Full Analysis Set — -0.2778; 0.0229 FEV1 liters/ eosinophils 10^9/liter — p=0.2407
Phase 2 N=30 A Study of Pertuzumab in Combination With Trastuzumab and Chemotherapy in Patients With HER2-Positive Advanced Gastric Cancer
Gastric Cancer
Primary: Percentage of Participants With Day 43 Serum Pertuzumab Trough Concentrations (Cmin) Greater Than or Equal to (>=) 20 Microgram Per Milliliter (mcg/mL) — 91.6; 98.3…
Phase 2 N=61 A Study of Gemcitabine-Cisplatin Chemotherapy Plus Necitumumab in the First-Line Treatment of Participants With Squamous Lung Cancer
Non-small Cell Lung Cancer
Primary: Percentage of Participants Who Achieve Best Overall Tumor Response of Complete Response (CR) or Partial Response (PR) Objective Tumor Response Rate (ORR) — 48.1…
Phase 1 N=99 A Study to Investigate the Safety, Tolerability, and Pharmacokinetics (PK) of Oseltamivir and Its Carboxylate Metabolite, RO0640802 in Healthy Participants
Healthy Volunteer
Primary: Area Under the Plasma Concentration-Time Curve From Time 0 to 12 Hour (AUC0-12h) of Oseltamivir and RO0640802 at Steady State — 581; 1143; 4147; 7966 ng*hour/mL
Phase 3 N=1,584 Uptitration Trial of Flibanserin Versus Placebo in Premenopausal Women With Hypoactive Sexual Desire Disorder
Sexual Dysfunctions, Psychological
Primary: Change From Baseline in the Frequency of Satisfying Sexual Events (SSE) as Recorded in the eDiary. — 1.4; 1.4; 1.9; 1.1 SSEs per 28 days